Clinical Utility of Genomic Profiling Tests in Patients with Advanced Gastrointestinal Cancers

ConclusionsAlthough their genomic profiles revealed fewer druggable sites, patients with GI cancers accessed targeted therapies similarly to patients with non-GI cancers. The utility of genomic profile testing in patients with GI cancers was highlighted to determine if patients can receive specific treatments, such as HER2-targeted and BRAF-targeted therapies.

http://link.springer.com/10.1007/s11523-022-00871-4

Source: Targeted Oncology - April 2, 2022 Category: Cancer & Oncology Source Type: research